Kestra Medical Technologies, Ltd.

What they do

The company describes itself as a wearable medical device and digital healthcare company focused on cardiovascular disease, using monitoring and therapeutic intervention technologies it characterizes as intuitive, intelligent and connected. Its revenue comes from WCDs. The business was conducted through West Affum Intermediate Holdings Corp. until the March 7, 2025 IPO, when that entity became a wholly owned subsidiary of Kestra Medical Technologies, Ltd. and serves as predecessor for financial reporting.

Revenue drivers

• Wearable cardioverter defibrillators (WCD) — The only product line identified in the filings; total revenue was $31.0 million in F1Q27 and $95.1 million in FY26. Segment-level revenue is not broken out.
• WCD market expansion — Cited as a factor behind the 60% F1Q27 revenue increase, alongside competitive share gains and new sales territories.
• In-network patient mix — A higher mix of in-network patients was cited as a driver of both revenue growth and the gross margin expansion to 56.5% in F1Q27.
• Revenue cycle management — Ongoing improvements in revenue cycle management capabilities were cited as a contributor to F1Q27 revenue growth.

Recent performance

F1Q27 (quarter ended July 31, 2026) revenue was $31.0 million, up 60% versus the prior-year period. Gross profit was $17.5 million versus $8.9 million, with gross margin expanding to 56.5% from 45.7%. GAAP operating expenses rose to $55.2 million from $37.7 million, and GAAP net loss widened to $44.1 million from $25.8 million. Adjusted EBITDA loss was $24.0 million versus $19.4 million a year earlier. Cash, cash equivalents and investments totaled $244.7 million at July 31, 2026, or approximately $320 million of total liquidity including committed unused term loan availability.

Strategy

Management points to innovation and commercial expansion as the basis for what it calls durable, top-tier growth. In F1Q27 the company increased spending on commercial expansion and accelerated investment in key R&D programs, which it says drove the increase in adjusted operating expenses. It also points to execution on planned cost improvement programs as a margin lever. CEO Brian Webster frames execution for prescribers and patients as the mechanism for market expansion and progress toward market leadership.

Risks

• GAAP losses are widening despite revenue growth — FY26 net loss was $131.6 million and F1Q27 GAAP net loss was $44.1 million, versus $25.8 million in the prior-year period.
• Sustained cash consumption — Operating cash flow was negative every reported year — $72.2M (2024), $77.6M (2025) and $81.7M (2026) — and the F1Q27 adjusted EBITDA loss was $24.0 million.
• Expense growth outpacing revenue in the quarter — F1Q27 GAAP operating expenses grew to $55.2 million from $37.7 million against $31.0 million of revenue, so gross profit of $17.5 million did not cover operating costs.
• Single product line — The filings only identify wearable cardioverter defibrillators as the revenue source, so performance depends on that one product category.

Outlook

Management raised FY27 revenue guidance to $141 million, representing 48% growth versus FY26, up from prior guidance of $137 million. That compares with reported FY26 revenue of $95.1 million. The company reports total liquidity of approximately $320 million, including committed unused term loan availability. No guidance for net income, EBITDA or cash flow is given in the excerpt.